ORIC to Participate at BTIG Biotech Conference

SAN FRANCISCOOct. 22, 2018 /PRNewswire/ — ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, announced today that it will participate in the BTIG Biotech Conference, which is being held in New York on October 25, 2018, at the Langham Hotel.  Chief Executive Officer Jacob Chacko will host one-on-one investor meetings.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC’s lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC’s pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC’s scientific founders are Drs. Charles Sawyers, MD and Scott Lowe, PhD, who have records of discovering innovative treatments and targets in cancer.  The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing.  ORIC is funded by leading biotechnology investors, including The Column GroupTopspin PartnersOrbiMed AdvisorsEcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.

ORIC Pharmaceuticals is headquartered in South San Francisco, California. For more information, please visit the Company’s website at http://www.oricpharma.com.